Used in research settings as a potent and selective inhibitor of the menin-MLL (mixed lineage leukemia) protein-protein interaction, making it a valuable tool compound in studies targeting MLL-rearranged leukemias. It demonstrates strong anti-leukemic activity in cellular and animal models by disrupting oncogenic gene expression driven by the MLL fusion proteins. Due to its ability to cross the blood-brain barrier, it is also explored for potential activity against central nervous system involvement in leukemia. Primarily employed in preclinical research to validate menin inhibition as a therapeutic strategy and to guide the development of clinical candidates for acute leukemias.